Design Therapeutics Past Earnings Performance
Past criteria checks 0/6
Design Therapeutics's earnings have been declining at an average annual rate of -31.9%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 136.2% per year.
Key information
-31.9%
Earnings growth rate
-16.3%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -136.2% |
Return on equity | -18.9% |
Net Margin | n/a |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Oct 04Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Jun 19Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Mar 15Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Nov 16Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation
Jun 06Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Feb 09Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Oct 25Design Therapeutics GAAP EPS of -$0.27 misses by $0.02
Aug 08We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate
Jul 02Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Mar 18Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Dec 03Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation
Aug 18Design Therapeutics expands board of directors
Jun 07Design Therapeutics EPS misses by $0.24
May 10Revenue & Expenses Breakdown
How Design Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 0 | -48 | 18 | 0 |
30 Jun 24 | 0 | -51 | 19 | -13 |
31 Mar 24 | 0 | -59 | 20 | 0 |
31 Dec 23 | 0 | -67 | 21 | 0 |
30 Sep 23 | 0 | -72 | 22 | 0 |
30 Jun 23 | 0 | -74 | 21 | 30 |
31 Mar 23 | 0 | -69 | 20 | 0 |
31 Dec 22 | 0 | -63 | 19 | 0 |
30 Sep 22 | 0 | -57 | 18 | 0 |
30 Jun 22 | 0 | -51 | 16 | 0 |
31 Mar 22 | 0 | -43 | 14 | 0 |
31 Dec 21 | 0 | -36 | 11 | 0 |
30 Sep 21 | 0 | -28 | 8 | 0 |
30 Jun 21 | 0 | -19 | 6 | 0 |
31 Mar 21 | 0 | -13 | 4 | 0 |
31 Dec 20 | 0 | -8 | 2 | 0 |
31 Dec 19 | 1 | -2 | 1 | 0 |
Quality Earnings: DSGN is currently unprofitable.
Growing Profit Margin: DSGN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DSGN is unprofitable, and losses have increased over the past 5 years at a rate of 31.9% per year.
Accelerating Growth: Unable to compare DSGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DSGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: DSGN has a negative Return on Equity (-18.93%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 12:11 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Design Therapeutics, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Madhu Kumar | Goldman Sachs |
Joseph Schwartz | Leerink Partners LLC |
Yasmeen Rahimi | Piper Sandler Companies |